ArticleNutrients2018
Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.
Article in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease: a meta-analysis.Surgery today · 2020Pooled it
- Systematic review of nutrition screening and assessment in inflammatory bowel disease.World journal of gastroenterology · 2019Pooled it
- The trend of obesity and inflammatory bowel disease in Australia and New Zealand: a bi-nation cohort study.Internal medicine journal · 2026Article
- Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.Current diabetes reports · 2026Review
- Muscle Function Impairment in Crohn's Disease Patients: Risk Factors and Clinical Implications-Single-Tertiary-Center Experience.Life (Basel, Switzerland) · 2026Article
- Observational
- Creeping fat is associated with transmural healing in patients with Crohn's disease receiving ustekinumab.Insights into imaging · 2025Article
- Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.Intestinal research · 2025Review
- MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease.Insights into imaging · 2025Article
- Relationship of visfatin with obesity and osteoporosis in patients with inflammatory bowel disease: a narrative review.Frontiers in immunology · 2025Review
- Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease.Biomedicines · 2024Review
- Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Observational
- Impact of malnutrition and sarcopenia on quality of life in patients with inflammatory bowel disease: A multicentre study.Journal of cachexia, sarcopenia and muscle · 2023Observational
- Causal effects of inflammatory bowel diseases on the risk of kidney stone disease: a two-sample bidirectional mendelian randomization.BMC urology · 2023Article
- Body Composition in Inflammatory Bowel Disease.Archives of Iranian medicine · 2023Review
- CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.EClinicalMedicine · 2023Article
- Age, body composition parameters and glycaemic control contribute to trabecular bone score deterioration in acromegaly more than disease activity.Frontiers in endocrinology · 2023Article
- A bidirectional Mendelian randomization study of sarcopenia-related traits and inflammatory bowel diseases.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundRising rates of obesity have been reported in patients with inflammatory bowel disease (IBD); however, prospective data is lacking. The aim of this study is to prospectively evaluate body composition in adults with IBD over 24 months.
methodsWhole body dual energy X-ray absorptiometry (DXA) data was performed at 0 months, 12 months, and 24 months. Bone mineral density (BMD), fat mass index (FMI (kg)/height (m²)), appendicular skeletal muscle index (ASMI (kg)/height (m²)), visceral adipose tissue and the visceral adipose height index (VHI, VAT area (cm³)/height (m²)), and clinical and anthropometric assessments were performed at each time point. Multivariable linear mixed effects regression analyses were performed.
resultsInitially, 154 participants were assessed at baseline (70% Crohn's disease, 55% male, median age 31 years), of whom 129 underwent repeated DXA at 12 months, and 110 underwent repeated DXA at 24 months. Amongst those undergoing repeated DXA, their body mass index (BMI) significantly increased over time, such that by 24 months, 62% of patients were overweight or obese (annual change BMI β = 0.43, 95%CI = [0.18, 0.67],
conclusionIncreasing rates of obesity in patients with IBD coincide with decreases in lean muscle mass over time, while high rates of osteopenia remain stable. These previously undocumented issues warrant attention in routine care to prevent avoidable morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.